Analyst ratings are a key indicator of a stock's potential performance. In the case of Zentalis Pharma, all six ratings received in the last quarter are bullish or somewhat bullish, indicating a positive outlook for the stock. The average price target of $43.83 also suggests a significant upside from the current price of $11.94. However, it's worth noting that this average price target represents a 14.48% decrease from the previous average of $51.25.